The manufacturing facilities, Jubilant HollisterStier, LLC (JHS) located at Spokane, Washington state, was inspected between April 15 and May 10, 2013, the US Food and Drug Administration (USFDA) said in a warning letter to company's CEO Marcelo A Morales.
Also Read: Sun Pharma gets USFDA approval for generic Cymbalta
Investigators from USFDA found significant violations of current good manufacturing practice (CGMP) regulations for finished pharmaceuticals, it added.
"The violations cause your drug products to be adulterated within the meaning of Section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 USC 351 (a)(2)(B), in that the methods used in, or the facilities or controls used for, their manufacture, processing, packing, or holding do not conform to, or are not operated or administered in conformity with CGMP," USFDA said.
One of the specific violations which the investigators found was failure to establish written procedures, that are designed to prevent microbiological contamination of drug products purporting to be sterile, and that include validation of all aseptic and sterilisation processes, it added.
The other violation was failure to adequately document all work orders associated with the April 2013 shutdown and include appropriate quality unit oversight.
"Your firm failed to assure an adequate system for cleaning and disinfecting aseptic processing areas and equipment," USFDA said.
"The company should take prompt action to correct the violations cited in this letter. Failure to promptly correct these violations may result in legal action without further notice including, without limitation, seizure and injunction," it added.
"Within fifteen working days of receipt of this letter, please notify this office in writing of the specific steps that you have taken to correct and prevent the recurrence of violations, and provide copies of supporting documentation," USFDA said.
According to the company's website, the Spokane plant contract manufactures sterile injectables and allergenic extract.
Shares of Jubilant Life Sciences today ended at Rs 116.50 per scrip on BSE, down 2.51 percent from its previous close.
Jubilant Life stock price
On December 12, 2013, Jubilant Life Sciences closed at Rs 116.50, down Rs 3, or 2.51 percent. The 52-week high of the share was Rs 237.90 and the 52-week low was Rs 65.10.
The latest book value of the company is Rs 116.89 per share. At current value, the price-to-book value of the company was 1.00.
Anda sedang membaca artikel tentang
USFDA issues warning to Jubilant Life over CGMP norms
Dengan url
http://kebugaranhidup.blogspot.com/2013/12/usfda-issues-warning-to-jubilant-life.html
Anda boleh menyebar luaskannya atau mengcopy paste-nya
USFDA issues warning to Jubilant Life over CGMP norms
namun jangan lupa untuk meletakkan link
USFDA issues warning to Jubilant Life over CGMP norms
sebagai sumbernya
0 komentar:
Posting Komentar